Clare Moore1, Gillian Corbett1, Alan C Moss2. 1. Center for Inflammatory Bowel Disease, Division of Gastroenterology, BIDMC, Boston, MA, USA. 2. Center for Inflammatory Bowel Disease, Division of Gastroenterology, BIDMC, Boston, MA, USA amoss@bidmc.harvard.edu.
Abstract
BACKGROUND AND AIMS: A number of observational studies have reported an association between serum levels of infliximab [IFX] at various thresholds, and clinical outcomes in inflammatory bowel disease [IBD]. This association has not previously been systematically analysed. METHODS: Systematic review of studies that reported serum infliximab levels according to outcomes in IBD. Primary outcome was clinical remission, and secondary outcomes included endoscopic remission, C-reactive protein [CRP] levels, and colectomy. Meta-analysis of raw data was performed where appropriate. A quality assessment was also undertaken. RESULTS: A total of 22 studies met the inclusion criteria, including 3483 patients; 12 studies reported IFX levels in a manner suitable for determining effect estimates. During maintenance therapy, patients in clinical remission had significantly higher mean trough IFX levels than patients not in remission: 3.1 µg/ml versus 0.9 µg/ml. The standardised mean difference in serum IFX levels between groups was 0.6 µg/ml (95% confidence interval [CI] 0.4-0.9, p = 0.0002]. Patients with an IFX level > 2 µg/ml were more likely to be in clinical remission (risk ratio [RR] 2.9, 95% CI 1.8-4.7, p < 0.001], or achieve endoscopic remission [RR 3, 95% CI 1.4-6.5, p = 0.004] than patients with levels < 2 µg/ml. CONCLUSIONS: There is a significant difference between serum infliximab levels in patients with IBD in remission, compared with those who relapse. A trough threshold during maintenance > 2 µg/ml is associated with a greater probability of clinical remission and mucosal healing.
BACKGROUND AND AIMS: A number of observational studies have reported an association between serum levels of infliximab [IFX] at various thresholds, and clinical outcomes in inflammatory bowel disease [IBD]. This association has not previously been systematically analysed. METHODS: Systematic review of studies that reported serum infliximab levels according to outcomes in IBD. Primary outcome was clinical remission, and secondary outcomes included endoscopic remission, C-reactive protein [CRP] levels, and colectomy. Meta-analysis of raw data was performed where appropriate. A quality assessment was also undertaken. RESULTS: A total of 22 studies met the inclusion criteria, including 3483 patients; 12 studies reported IFX levels in a manner suitable for determining effect estimates. During maintenance therapy, patients in clinical remission had significantly higher mean trough IFX levels than patients not in remission: 3.1 µg/ml versus 0.9 µg/ml. The standardised mean difference in serum IFX levels between groups was 0.6 µg/ml (95% confidence interval [CI] 0.4-0.9, p = 0.0002]. Patients with an IFX level > 2 µg/ml were more likely to be in clinical remission (risk ratio [RR] 2.9, 95% CI 1.8-4.7, p < 0.001], or achieve endoscopic remission [RR 3, 95% CI 1.4-6.5, p = 0.004] than patients with levels < 2 µg/ml. CONCLUSIONS: There is a significant difference between serum infliximab levels in patients with IBD in remission, compared with those who relapse. A trough threshold during maintenance > 2 µg/ml is associated with a greater probability of clinical remission and mucosal healing.
Authors: C Lahiff; P Safaie; A Awais; M Akbari; L Gashin; S Sheth; A Lembo; D Leffler; A C Moss; A S Cheifetz Journal: Aliment Pharmacol Ther Date: 2013-02-21 Impact factor: 8.171
Authors: Niels Vande Casteele; Ann Gils; Sharat Singh; Linda Ohrmund; Scott Hauenstein; Paul Rutgeerts; Séverine Vermeire Journal: Am J Gastroenterol Date: 2013-02-19 Impact factor: 10.864
Authors: Casper Steenholdt; Klaus Bendtzen; Jørn Brynskov; Ole Ø Thomsen; Mark A Ainsworth Journal: Am J Gastroenterol Date: 2014-05-06 Impact factor: 10.864
Authors: R Khanna; B D Sattin; W Afif; E I Benchimol; E-J Bernard; A Bitton; B Bressler; R N Fedorak; S Ghosh; G R Greenberg; J K Marshall; R Panaccione; E G Seidman; M S Silverberg; A H Steinhart; R Sy; G Van Assche; T D Walters; W J Sandborn; B G Feagan Journal: Aliment Pharmacol Ther Date: 2013-07-14 Impact factor: 8.171
Authors: Joseph C Marini; Jocelyn Sendecki; Freddy Cornillie; John W Popp; Shawn Black; Marion Blank; Ann Gils; Thomas Van Stappen; Dörte Hamann; Theo Rispens; Lina Thérien; Kelly Chun; Gopi Shankar Journal: AAPS J Date: 2016-09-06 Impact factor: 4.009
Authors: Laura E Bauman; Ye Xiong; Tomoyuki Mizuno; Philip Minar; Tsuyoshi Fukuda; Min Dong; Michael J Rosen; Alexander A Vinks Journal: Inflamm Bowel Dis Date: 2020-02-11 Impact factor: 5.325
Authors: Thomas Van Stappen; Lize Bollen; Niels Vande Casteele; Konstantinos Papamichael; Gert Van Assche; Marc Ferrante; Séverine Vermeire; Ann Gils Journal: Clin Transl Gastroenterol Date: 2016-12-08 Impact factor: 4.488
Authors: Karoline Freeman; Sian Taylor-Phillips; Martin Connock; Rachel Court; Alexander Tsertsvadze; Deepson Shyangdan; Peter Auguste; Hema Mistry; Ramesh Arasaradnam; Paul Sutcliffe; Aileen Clarke Journal: BMJ Open Date: 2017-07-02 Impact factor: 2.692